BridgeBio shifts filing plans for rare disease drug after Phase 3 success

BridgeBio on Monday trumpeted positive results from a Phase 3 rare disease study, potentially setting the company up with a stronger FDA pitch than it had originally thought. In the study’s interim analysis, BridgeBio’s drug ...